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Objective: Endochondral ossiﬁcation, a conversion process from nonvascularized and hypoxic cartilage to
highly vascularized bone, plays a crucial role in osteoarthritis (OA) development as well as in physio-
logical skeletal growth. We have shown that hypoxia-inducible factor-2a (HIF-2a, encoded by EPAS1) is
an extensive regulator of the endochondal ossiﬁcation process. Here we review the possible signaling
network regulating OA development on the axis of HIF-2a.
Methods: Peer reviewed publications published prior to August 2010 were searched in the Pubmed
database. Articles that were relevant to HIF and molecular mechanisms of the endochondral ossiﬁcation
and OA were selected.
Results: As a trigger of OA, mechanical stress may induce the upstream NF-kB signal and HIF-2a
expression in joint cartilage of mice and humans, which causes transactivation of endochondral ossiﬁ-
cation-related molecules with the most potent b-subunit partner aryl hydrocarbon nuclear translocator-
like (ARNTL). In contrast to HIF-2a, HIF-1a functions to maintain cartilage via a distinct mechanism, so
that the shifting of the HIFs might possibly be involved in an OA pathogenesis.
Conclusion: Signals on the HIF-2a axis from NF-kB signaling to the endochondral ossiﬁcation-related
molecules, possibly in combination with HIF-2a and ARNTL, may represent a rational therapeutic target
for OA with minimal effects on physiological skeletal homeostasis.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Although osteoarthritis (OA) is today considered a major public
health issue causing chronic disability worldwide in the increasing
number of aging people1,2, this disorder is far behind other skeletal
diseases like osteoporosis and rheumatoid arthritis in the disease-
modifying treatments which have been developed. This is mainly
because little is known about the underlying molecular mechanism
which is the therapeutic target. Recent studies using experimental
mouse models with surgical instability in the knee joints have
shown that OA is initiated by production of proteases like matrix
metalloproteinase-13 (MMP-13) and a disintegrin and metal-
loproteinase with thrombospondin motif-5 (ADAMTS-5)3e5.
However, trials applying the protease inhibitors for clinical use as
a disease-modifying treatment have to date been unsuccessful
because of insufﬁcient efﬁciency and adverse events6e8. Hence,
a number of alternative or complementary approaches to selective
protease inhibition merit consideration.o: H. Kawaguchi, Sensory &
rsity of Tokyo, Hongo 7-3-1,
30473; Fax: 81-33818-4082.
. Kawaguchi).
s Research Society International. PEndochondral ossiﬁcation process in OA development
We and others have reported that the endochondral ossiﬁcation
process plays a crucial role not only in physiological skeletal
growth, but also in OA development9e19. In other words, OA
involves a reinitiation of the process that normally occurs in
embryos and children and ceases in adulthood. This process starts
with hypertrophic differentiation of chondrocytes characterized by
type X collagen (COL10A1) expression, followed by the conversion
of nonvascularized and hypoxic cartilage tissue into highly vascu-
larized bone tissue via degradation of the cartilage matrix and
vascular invasion20. The signals to induce endochondral ossiﬁcation
cause cartilage degradation at the center of the joint and osteo-
phyte formation at the periphery. The difference of the two sites
may depend on the vascularity. At the periphery, vascularity is
accessible from the synovium or tendon, which completes endo-
chondral ossiﬁcation and forms osteophytes, just as it does at the
embryonic and growth plate cartilage. However, in the center, the
vascularity is not accessible from the edge, remaining cartilage
degradation without being replaced by bone15,16.
Aiming at identiﬁcation of therapeutic targets for OA, we have
performed a screen of transcription factors that potentiate the
expression of COL10A1 and identiﬁed hypoxia-inducible factor-2aublished by Elsevier Ltd. All rights reserved.
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as the most potent transactivator21. Here we review the possible
signaling network regulating OAdevelopment on the axis of HIF-2a.
Physiological roles of HIF proteins in cartilage
The HIF proteins belong to the basic-helix-loop-helix/Per-ARNT-
Sim (bHLH/PAS) transcription factor family, and consist of a- and
b-subunit members22,23. Under normoxic conditions, the a-subunit
members HIF-1a, 2a and 3a undergo oxygen-dependent hydrox-
ylation, resulting in ubiquitination and degradation by the pro-
teasome24,25. In contrast, under hypoxic conditions, they are
neither hydroxylated nor degraded, and heterodimerize with the
constitutive b-subunit members. The heterodimers activate tran-
scription of the target genes by binding the consensus sequence
called hypoxia-responsive element in the promoters23. In fact,
HIF-1a plays essential roles to assure survival under hypoxic
conditions in various tissues by regulating vascularization, eryth-
ropoiesis iron metabolism, and glucose metabolism22. Although
HIF-2a is approximately 50% homologous to HIF-1a at the amino
acid level, their distributions, target genes, and functions are
notably different26e28. HIF-1a is expressed mainly in hypoxic,
poorly vascularized sites, while HIF-2a is also expressed in well-
vascularized tissues27,28.
In cartilage as well, the hypoxic condition enhances the expres-
sion and activity of HIF-1a24,29e31. HIF-1a is extensively localized in
chondrocytes from the earlier differentiation stages21,29e31, and
induces initial chondrogenesis, joint development, cartilage matrix
synthesis, and cell survival29e33. In contrast, HIF-2a is expressed
mainly in highly differentiated chondrocytes, and its function is
independent of oxygen-dependent hydroxylation, denying the
importance of HIF-2a for survival of hypoxic conditions in carti-
lage21,34,35. Likewise, although cartilage-speciﬁc knockout of HIF-1a
leads to defects in cartilage formation and chondrocyte survival31,33,
HIF-2a-haploinsufﬁcient mice exhibit mild and transient dwarﬁsm
at the embryonic stage with an elongation of the hypertrophic zone
and delayed ossiﬁcation in the limb cartilage, indicating that HIF-2a
insufﬁciency impairs not only chondrocyte hypertrophy but also
subsequent extensive steps of endochondral ossiﬁcation. In fact,
HIF-2a induces expressions of many key factors for these steps:
COL10A1, MMP-13, MMP-3, MMP-9, runt-related transcription
factor-2 (RUNX2), Indian hedgehog (IHH), and vascular endothelial
growth factor (VEGF)21. Hence, HIF-1a andHIF-2amayhave distinct
roles via different mechanisms: hypoxia-dependent cartilage
formation and maintenance by HIF-1a and hypoxia-independent
endochondral ossiﬁcation by HIF-2a.
HIF b-subunit partner of HIF-2a
The HIF a-subunit member functions by forming a heterodimer
with a b-subunit member22,23. The representative b-subunit is the
aryl hydrocarbon nuclear translocator (ARNT or HIF-1b), previously
identiﬁed as a binding partner of the dioxin/aryl hydrocarbon
receptor (DR/AhR)36. ARNT-like (ARNTL, BMAL1 or MOP3) is well
characterized as a regulator of circadian rhythms, working as
a heterodimer with CLOCK37. ARNT2 (HIF-2b) and ARNTL2 (BMAL2
or CLIF) are identiﬁed as homologs of ARNT and ARNTL,
respectively38e40. In the mouse cartilage, while ARNT and ARNT2
are extensively expressed in chondrocytes of all differentiation
stages, ARNTL and ARNTL2 are expressed in highly differentiated
chondrocytes, just like HIF-2a21. Although all b-subunit members
are physically associated with HIF-2a as previously reported40e43,
ARNTL shows the strongest binding afﬁnity to HIF-2a and
enhancement of the HIF-2a transactivation of COL10A1,MMP13 and
VEGFA21. Meanwhile, ARNTL-null mice show impaired circadianrhythms and ectopic ossiﬁcation with age without abnormality in
skeletal development or joint cartilage44. Hence, ARNTL seems to
be the most potent b-subunit partner of HIF-2a in chondrocytes,
although all b-subunit members may be involved in the regulation
of HIF-2a function in cartilage.
Roles of HIF-2a in OA development
Chun’s group and ours have recently described a central role of
HIF-2a in the OA development21,35. HIF-2a is highly expressed in
the OA cartilage of the mouse experimental model and human
surgical specimens. Despite the mild and transient phenotype in
the embryonic skeletal development under physiological condi-
tions, HIF-2a-haploinsufﬁcient mice show a marked resistance to
cartilage degradation and osteophyte formation under the OA
induction in the knee joints with decreased expressions of endo-
chondral ossiﬁcation-related factors as well as catabolic factors
including MMPs, nitric oxide synthase-2 (NOS2) and prosta-
glandin-endoperoxide synthase-2 (PTGS2)21,35. In contrast, carti-
lage destruction is enhanced in mice with chondrocyte-speciﬁc
overexpression of HIF-2a and with intra-articular injection of the
HIF-2a adenovirus, accompanied by increased expressions of the
catabolic factors35. Furthermore, human genomic analyses using
a Japanese population-based cohort of the ROAD study45 have
identiﬁed a functional single nucleotide polymorphism (SNP) in the
human HIF-2a gene which is associated with knee OA21.
OA reﬂects an imbalance between matrix anabolic and catabolic
processes in joint cartilage, so that the protection is achieved by
induction of anabolism or inhibition of catabolism. The protection
in the HIF-2a-haploinsufﬁcient mice is not likely to be due to
induction of anabolism, as the anabolic markers like type II collagen
and aggrecan are unaffected in the joint cartilage21,35. Because
MMP-13-null mice are reported to be protected from cartilage
degradation after surgical OA induction4, similarly to HIF-2a-hap-
loinsufﬁcient mice, the OA protection caused by the HIF-2a insuf-
ﬁciency might occur principally through regulation of MMP-13.
Notably, although recent studies have identiﬁed ADAMTS-5 and
related molecules like syndecan-4 as key catabolic regulators of OA
development3,5,46,47, ADAMTS-5 is not altered by the over-
expression or knockout of HIF-2a, implicating an independent
pathway21,35. Besides catabolic factors, HIF-2a induces osteogenic
factors like RUNX2, IHH and VEGF21. RUNX2 is a mediator of
chondrocyte hypertrophy and of MMP-13 expression just weeks
into the course of the experimental mouse knee OA model14.
However, RUNX2 does not seem to be essential for the OA induction
by HIF-2a, since overexpression of the dominant negative mutant
does not affect the HIF-2a functions21. The IHH signal is also shown
to promote OA development as well as the physiological skeletal
growth, although being partly mediated by RUNX2 expression47.
VEGF is a well-characterized growth factor inducing angiogenesis,
and a representative target gene of HIF-1a31,48. VEGF may be
a major mediator for the osteophyte formation induced by HIF-2a,
since this is highly expressed in the periphery of OA cartilage21.
Chun’s group and ours agree that the NF-kB signal is an
upstream mechanism that regulates HIF-2a, since IL-1b and TNF-a,
putative ligands for the NF-kB signal, increase the HIF-2a expres-
sion in chondrocytes21,35. A screening using the HIF-2a promoter
assay identiﬁed v-rel reticuloendotheliosis viral oncogene homolog
A (RelA or NF-kB p65), an NF-kB family member, as the most potent
transactivator, and determined an NF-kB motif as the core
responsive region by mutagenesis analysis21. The RelA expression
was induced alongside the HIF-2a expression during OA develop-
ment, and the SNP described above is involved in the HIF-2a
induction by the NF-kB signal. Considering that the NF-kB signal is
activated not only by inﬂammatory stimulation, but also by
Fig. 1. Schematic overview of signal transductions on the axis of HIF proteins in the maintenance of cartilage homeostasis and OA development.
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mediator from mechanical stress to OA development in joint
cartilage.
Since HIF-1a functions to maintain cartilage while HIF-2a to
induce endochondral ossiﬁcation and cartilage degradation, the
shift from HIF-1a to HIF-2a might possibly be a pathogenesis of
OA29e31,51,52 (Fig. 1). A recent study shows that the autophagic
response is promoted by HIF-1a and antagonized by HIF-2a in
chondrocytes53. Due to the difference of sensitivity to the oxygen
level between HIF-1a and HIF-2a, the oxic conditions in cartilage
may regulate the shift of the HIF proteins. Hence, prolyl hydroxy-
lases which become active in the presence of oxygen and target the
HIFs for hydroxylation and degradation may be involved in the OA
pathogenesis.
Prospects
HIF-2a is an extensive regulator of endochondral ossiﬁcation
process during OA development21. As a trigger of OA, mechanical
stressmay induce the upstreamNF-kB signal andHIF-2a expression
in joint cartilage, which cause endochondral ossiﬁcation by trans-
activation of COL10A1, MMP13, VEGFA and other osteogenic factors.
Signals in the HIF-2a axis fromNF-kB signaling to the endochondral
ossiﬁcation-related molecules may represent a rational therapeutic
target for OA with minimal effects on physiological skeletal
homeostasis. However, there are several issues to be resolved before
the clinical application to human OA treatment. First, HIF-2a in
cartilage may be difﬁcult to target with a systemic drug because
cartilage lacks vasculature. Moreover, since HIF-2a is known to have
physiological protective functions against neuronal oxidative stress
and normoxic oxidative neuronal death54, the safety margin for
systemic administration of a HIF-2a inhibitor may be limited. One
solution to these challenges might be to administer the HIF-2a
inhibitor by intra-articular injection. Although joint cartilage cells
would take up the injected inhibitor via diffusion fromsynovial ﬂuid
and surrounding joint tissue, transcription factors are still difﬁcultto target. Hence, we need to establish a suitable drug delivery
system which is effective and selective to chondrocytes. Secondly,
although HIF-2a expression is induced in the earlier stage of OA
lesions, it is downregulated in the late stages21,35, suggesting that
the timewindow for using the inhibitor may be narrow. For the late
stage of OA, anabolic signals related to HIF-1a might be useful.
Modulation of ARNTL which functions as a potent partner of HIF-2a
but not of HIF-1a21might be useful for the switching fromHIF-2a to
HIF-1a. Further systems biology of chondrocyte differentiation and
potential regulatory effects of chondrocyte microRNAs55,56 on the
HIF protein expressions may alsomerit further investigation. Lastly,
it may be more efﬁcient to identify the extracellular signal that
either directly activates or suppresses HIF-2a, because this might be
easier to target than intracellular signals.
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